Everolimus overcomes trastuzumab resistance in HER2+ early breast cancer Oncology Nurse Advisor Some patients with early breast cancer had a benefit in clinical response rate when everolimus was added to trastuzumab treatment, though the benefit was statistically nonsignificant. These puzzling results suggested that this benefit was independent ... |
